中新集團(601512.SH):擬出資不超5000萬元參與投資無錫毓立基金
格隆匯 10 月 13日丨中新集團(601512.SH)公佈,公司擬作為有限合夥人以自有資金參與投資無錫毓立基金,重點投資先進製造、新材料、電子、5G通信、生物醫療、TMT等戰略新興行業。無錫毓立基金已於2019年11月25日完成工商註冊,並於2019年12月20日完成中國證券投資基金業協會備案(基金編號:SJL799),首次關閉規模為1.7556億元。無錫毓立基金本輪擬主要引進多家機構投資者,最終目標規模為2.8億元左右。公司擬認繳出資不超過5000萬元且佔比不超過最終認繳總額的20%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.